9 completed. 9 Phase 2, 4 Phase 3.
By phase and status
Follow HCV: new trials by email Literature Review of HCV trials Research Report on HCV
Trials (filtered) newest first · largest first
All 9 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV Bemnifosbuvir, Ruzasvir - Chronic Hepatitis C Virus, Hepatitis C, Chronic Phase 2 Completed 275 2023-05-30 2025-10-21 Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters Sofosbuvir +daclatasvir+ simeprevir+Ribavirin - Male Infertility, HCV Phase 2 / Phase 3 Completed 200 2022-03-01 2023-02-08 Utilization of Hepatitis C Positive Kidneys in Negative Recipients Sofosbuvir / Velpatasvir Oral Tablet [Epclusa], Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet [MAVYRET] - Kidney Transplant, Hepatitis C Phase 2 / Phase 3 Completed 54 2019-03-22 2023-09-13 Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects. Ravidasvir, Danoprevir, Ritonavir - HCV Phase 2 / Phase 3 Completed 425 2017-07-01 2020-07-28 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of ABT-493 and ABT-530 With and Without Ribavirin in Adults With HCV Who Failed a Prior DAA Containing Therapy ABT-493, ABT-530, ribavirin (RBV), ABT-493/ABT-530 - Chronic Hepatitis C, Hepatitis C Virus Phase 2 / Phase 3 Completed 141 2015-04-01 2017-09-15 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection ABT-493, ABT-530 - Chronic Hepatitis C, Hepatitis C Virus Phase 2 Completed 174 2014-08-01 2021-07-13 A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C VX-135, Daclatasvir - Chronic Hepatitis C, CHC Phase 2 Completed 23 2013-06-01 2015-12-29 A Pilot Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of ABT-450 With Ritonavir (ABT-450/r) Dosed in Combination With ABT-072 and Ribavirin (RBV) ABT-450, ABT-072, Ribavirin - Hepatitis C, HCV Phase 2 Completed 11 2010-10-01 2015-01-08 A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 ABT-450, ABT-072, ABT-333 - Hepatitis C, HCV Phase 2 Completed 74 2010-03-01 2015-01-08
Narrower conditions Hepatitis C (7) · Hepatitis C, Chronic (4) · Infertility, Male (1) · Liver Cirrhosis (1)
Broader conditions Blood-Borne Infections (7) · Communicable Diseases (7) · Digestive System Diseases (7) · Flaviviridae Infections (7) · Hepatitis (7) · Hepatitis, Viral, Human (7) · Infections (7) · Liver Diseases (7) · RNA Virus Infections (7) · Virus Diseases (7) · Chronic Disease (4) · Disease Attributes (4) · Hepatitis, Chronic (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4)
Interventions Ribavirin (4) · Ritonavir (3) · glecaprevir (3) · pibrentasvir (3) · ABT-072 (2) · glecaprevir and pibrentasvir (2) · paritaprevir (2) · AT-511 (1) · Sofosbuvir (1) · daclatasvir (1) · danoprevir (1) · dasabuvir (1) · ombitasvir (1) · ravidasvir (1) · ruzasvir (1)
Sponsors AbbVie (2) · AbbVie (prior sponsor, Abbott) (2) · Ascletis Pharmaceuticals Co., Ltd. (1) · Atea Pharmaceuticals, Inc. (1) · Benha University (1) · Ohio State University (1) · Vertex Pharmaceuticals Incorporated (1)
Countries United States (4) · Brazil (1) · Canada (1) · China (1) · Egypt (1) · India (1) · Mauritius (1) · Moldova (1) · New Zealand (1) · Pakistan (1) · Philippines (1) · Puerto Rico (1) · Romania (1) · South Africa (1) · South Korea (1)
Top investigators Armen Asatryan, MD (1) · Daniel Cohen (1) · Daniel Cohen, MD (1) · Reem Daloul, MD (1) · Yahong Chen, Master (1)
Results publications PMID 30012435 , PMID 30923816 , PMID 30977945 , PMID 23439262 , PMID 25451053 , PMID 28128852 , PMID 28412293 , PMID 30868245 , PMID 31568620
NIH funding 2014 (1) , 2015 (1)